ArticleFrontiers in immunology2022

Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study.

Lu Si et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.